Rhythm Biosciences Ltd (ASX: RHY) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Rhythm Biosciences Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$62.73 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
337.01 million
Earnings per share
-0.024
Dividend per share
N/A
Year To Date Return
40.74%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Rhythm Biosciences Ltd (ASX: RHY)
Latest News
Share Gainers
Why is the Rhythm Biosciences (ASX:RHY) share price up 11% on Monday?
Healthcare Shares
Why is the Rhythm (ASX:RHY) share price climbing 10% today?
Share Gainers
Rhythm Biosciences (ASX:RHY) share price jumps 12% on key milestone
Share Gainers
Why the Rhythm Biosciences (ASX:RHY) share price is jumping 8% today
Healthcare Shares
Why the Rhythm Biosciences (ASX:RHY) share price is flying higher today
Share Gainers
Why ARB, Rhythm Biosciences, Sezzle, & Spark shares are storming higher
Share Gainers
Why the Rhythm Biosciences (ASX:RHY) share price is racing 6% higher
Healthcare Shares
Why the Rhythm (ASX:RHY) share price is climbing today
Healthcare Shares
Here's why the Rhythm (ASX:RHY) share price is soaring 8% today
Healthcare Shares
Rhythm (ASX:RHY) share price surges 10% on ColoSTAT results
Share Market News
What is going on with the Rhythm (ASX:RHY) share price today?
Share Market News
The Rhythm (ASX:RHY) share price surges on cancer testing milestone
RHY ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Rhythm Biosciences Ltd
Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. The product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. The company operates predominantly in one business and geographical segment which is the research and development of biosciences in Australia.
RHY Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 02 Apr 2026 | $0.19 | $-0.01 | -5.13% | 360,771 | $0.20 | $0.20 | $0.18 |
| 01 Apr 2026 | $0.20 | $0.02 | 11.11% | 1,669,734 | $0.18 | $0.21 | $0.18 |
| 31 Mar 2026 | $0.18 | $-0.02 | -10.26% | 864,374 | $0.19 | $0.19 | $0.18 |
| 30 Mar 2026 | $0.20 | $0.01 | 5.41% | 783,731 | $0.19 | $0.21 | $0.18 |
| 27 Mar 2026 | $0.19 | $-0.01 | -5.13% | 351,526 | $0.20 | $0.20 | $0.19 |
| 26 Mar 2026 | $0.20 | $-0.01 | -4.88% | 305,686 | $0.21 | $0.21 | $0.19 |
| 25 Mar 2026 | $0.21 | $0.01 | 5.13% | 151,128 | $0.20 | $0.21 | $0.20 |
| 24 Mar 2026 | $0.20 | $0.01 | 5.26% | 116,000 | $0.20 | $0.20 | $0.20 |
| 23 Mar 2026 | $0.19 | $-0.01 | -5.00% | 558,777 | $0.20 | $0.20 | $0.19 |
| 20 Mar 2026 | $0.20 | $-0.02 | -9.09% | 758,841 | $0.22 | $0.22 | $0.20 |
| 19 Mar 2026 | $0.22 | $-0.01 | -4.26% | 673,548 | $0.24 | $0.24 | $0.22 |
| 18 Mar 2026 | $0.24 | $0.02 | 9.52% | 2,587,810 | $0.22 | $0.25 | $0.21 |
| 17 Mar 2026 | $0.21 | $-0.01 | -4.65% | 537,318 | $0.22 | $0.22 | $0.20 |
| 16 Mar 2026 | $0.22 | $0.01 | 4.76% | 687,448 | $0.21 | $0.23 | $0.21 |
| 13 Mar 2026 | $0.21 | $0.01 | 5.00% | 551,328 | $0.21 | $0.22 | $0.20 |
| 12 Mar 2026 | $0.20 | $-0.02 | -8.89% | 1,156,021 | $0.22 | $0.22 | $0.20 |
| 11 Mar 2026 | $0.23 | $0.02 | 10.00% | 1,264,942 | $0.22 | $0.23 | $0.22 |
| 10 Mar 2026 | $0.20 | $0.00 | 0.00% | 607,074 | $0.20 | $0.23 | $0.20 |
| 09 Mar 2026 | $0.20 | $0.02 | 10.81% | 981,061 | $0.20 | $0.21 | $0.19 |
| 06 Mar 2026 | $0.19 | $0.01 | 5.56% | 197,938 | $0.19 | $0.20 | $0.19 |
| 05 Mar 2026 | $0.18 | $0.00 | 0.00% | 141,304 | $0.19 | $0.19 | $0.18 |
| 04 Mar 2026 | $0.18 | $-0.01 | -5.41% | 901,248 | $0.19 | $0.19 | $0.18 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 02 Dec 2025 | David Atkins | Issued | 100,000 | $8,600 |
Issue of options.
|
| 02 Dec 2025 | Gavin Fox-Smith | Issued | 277,777 | $23,888 |
Issue of options.
|
| 01 Dec 2025 | Gavin Fox-Smith | Issued | 750,000 | $66,000 |
Issue of options.
|
| 01 Dec 2025 | Gavin Fox-Smith | Issued | 1,027,777 | $99,999 |
Issue of securities.
|
| 01 Dec 2025 | Sue(Susan) MacLeman | Issued | 450,000 | $39,600 |
Issue of options.
|
| 01 Dec 2025 | Sue(Susan) MacLeman | Issued | 450,000 | $45,000 |
Issue of securities.
|
| 01 Dec 2025 | David Atkins | Issued | 1,093,001 | $108,300 |
Issue of securities.
|
| 01 Dec 2025 | David Atkins | Transfer | 4,000,000 | $352,000 |
Off-market transfer. assuming off market transfer
|
| 01 Dec 2025 | David Atkins | Issued | 466,820 | $41,080 |
Issue of options.
|
| 01 Dec 2025 | David Atkins | Transfer | 4,000,000 | $352,000 |
Off-market transfer. assuming off market transfer
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr David Atkins | Chief Executive OfficerManaging Director | May 2024 |
Dr Atkins is a healthcare leader with global markets experience across a board range of life sciences and healthcare disciplines, having gained experience in R&D, product development and commercialization across biotech, medical device, IVD and data-driven solutions in all global markets. Over the last 30 years, he has held national, regional and global roles across the Pharmaceutical, medical device and diagnostics sectors.
|
| Mr Gavin Fox-Smith | Non-Executive DirectorNon-Executive Chairman | Dec 2024 |
Mr Smith has 38-year experience in Medical Technology in Australia/NZ and Asia. He has also played lead Governance and Executive roles in Industry Bodies, Innovation Initiatives and Not for Profit Boards. Gavin is an advocate for Gender Equality and Indigenous Engagement. Gavin is Chair of ANDHealth (Australia's National Digital Health Initiative), Non-Executive Director for Omnigon, Bowel Cancer Australia and SAN Foundation.
|
| Ms Andrea Steele | Company SecretaryGeneral Counsel | Feb 2022 |
-
|
| Mr James Stephen Barrie | Joint Company Secretary | Dec 2023 |
-
|
| Mr Todd Perkinson | Chief Financial Officer |
-
|
|
| Andrea Steele | Company SecretaryGeneral Counsel |
-
|
|
| James Stephen Barrie | Joint Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Catapult Investors Pty Ltd | 22,479,168 | 7.91% |
| HSBC Custody Nominees (Australia) Limited | 17,982,996 | 6.33% |
| Newfound Investments Pty Ltd | 13,905,407 | 4.89% |
| Loumea Investment Pty Ltd | 8,052,520 | 2.83% |
| J P Morgan Nominees Australia Pty Limited | 6,522,164 | 2.30% |
| Rojo Nero Capital Pty Ltd | 4,541,619 | 1.60% |
| Dc & Pc Holdings Pty Ltd | 4,465,567 | 1.57% |
| Ferndale Securities Pty Ltd | 4,300,000 | 1.51% |
| BNP Paribas Nominees Pty Ltd | 4,224,507 | 1.49% |
| Mr Martin Paul Breslin <The Mpb A/C> | 4,000,000 | 1.41% |
| Giokirptyltd | 3,661,470 | 1.29% |
| Mr Martin Paul Breslin | 3,175,000 | 1.12% |
| Mr Mark Anthony Rogers & Mr Arthur Nicholas Veliss | 3,000,000 | 1.06% |
| Mr Adrian Darby | 2,512,328 | 0.88% |
| Commonwealth Scientific And Industrial Research Organisation | 2,500,000 | 0.88% |
| Finclear Services Nominees Pty Limited | 2,325,463 | 0.82% |
| E&W Nominee Pty Ltd | 2,207,941 | 0.78% |
| Ms Natalie Louise Patterson | 2,200,000 | 0.77% |
| Mrs Joan Margaret Molyneux & Mrs Wendy Anne Hutchison & Mr John Edward Hutchison | 2,150,000 | 0.76% |
| Mr Hsien Michael Soo | 2,134,442 | 0.75% |